Monopar Therapeutics (NASDAQ:MNPR) PT Raised to $6.00

Monopar Therapeutics (NASDAQ:MNPR) had its target price boosted by stock analysts at HC Wainwright from $2.00 to $6.00 in a research note issued on Wednesday, Benzinga reports. The brokerage currently has a “buy” rating on the stock. HC Wainwright’s price target indicates a potential upside of 158.62% from the stock’s current price. HC Wainwright also issued estimates for Monopar Therapeutics’ Q1 2025 earnings at ($2.75) EPS, Q2 2025 earnings at ($2.80) EPS, Q3 2025 earnings at ($2.85) EPS, Q4 2025 earnings at ($1.50) EPS and FY2028 earnings at $0.90 EPS.

Monopar Therapeutics Trading Down 4.1 %

NASDAQ MNPR traded down $0.10 during trading hours on Wednesday, reaching $2.32. The company’s stock had a trading volume of 31,765 shares, compared to its average volume of 450,548. The business has a 50-day simple moving average of $3.55 and a 200 day simple moving average of $3.41. Monopar Therapeutics has a 52 week low of $1.37 and a 52 week high of $8.65. The stock has a market cap of $40.56 million, a PE ratio of -4.46 and a beta of 1.18.

Monopar Therapeutics (NASDAQ:MNPR) last announced its quarterly earnings results on Friday, August 9th. The company reported ($0.10) EPS for the quarter, missing the consensus estimate of ($0.09) by ($0.01). As a group, equities analysts predict that Monopar Therapeutics will post -0.37 EPS for the current year.

Monopar Therapeutics Company Profile

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.